Orchard Cash Pile Set To Rise With Nasdaq IPO
The UK gene therapy firm was only set up in 2016 but after raising $260m in two financing rounds since the end of 2017, Orchard has filed documents with a view to listing on NASDAQ.
You may also be interested in...
In 2018, while biotech venture activity spoke mainly with an American accent, China emerged as the world’s third most active cluster, while the UK led the way in Europe.
October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.
Orchard Therapeutics will acquire GSK’s portfolio of approved and investigational rare disease gene therapies, including EU-approved Strimvelis and additional late-stage gene therapies.